LT2635257T - Pasiutligės glikoproteino į virusą panašios dalelės (vlps) - Google Patents
Pasiutligės glikoproteino į virusą panašios dalelės (vlps)Info
- Publication number
- LT2635257T LT2635257T LTEP11838942.8T LT11838942T LT2635257T LT 2635257 T LT2635257 T LT 2635257T LT 11838942 T LT11838942 T LT 11838942T LT 2635257 T LT2635257 T LT 2635257T
- Authority
- LT
- Lithuania
- Prior art keywords
- vlps
- particles
- rabies glycoprotein
- glycoprotein virus
- virus
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 206010037742 Rabies Diseases 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41076710P | 2010-11-05 | 2010-11-05 | |
| PCT/US2011/059602 WO2012061815A2 (en) | 2010-11-05 | 2011-11-07 | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2635257T true LT2635257T (lt) | 2017-09-25 |
Family
ID=46025156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11838942.8T LT2635257T (lt) | 2010-11-05 | 2011-11-07 | Pasiutligės glikoproteino į virusą panašios dalelės (vlps) |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9724405B2 (lt) |
| EP (2) | EP3246019B1 (lt) |
| JP (2) | JP6158088B2 (lt) |
| KR (1) | KR101847908B1 (lt) |
| CN (2) | CN109157658A (lt) |
| AU (1) | AU2011323090B2 (lt) |
| BR (1) | BR112013011194B1 (lt) |
| CA (1) | CA2817005C (lt) |
| CY (1) | CY1119284T1 (lt) |
| DK (1) | DK2635257T3 (lt) |
| ES (1) | ES2636965T3 (lt) |
| HR (1) | HRP20171213T1 (lt) |
| HU (1) | HUE034247T2 (lt) |
| LT (1) | LT2635257T (lt) |
| MX (1) | MX354750B (lt) |
| PL (1) | PL2635257T3 (lt) |
| PT (1) | PT2635257T (lt) |
| RS (1) | RS56157B1 (lt) |
| SG (1) | SG190140A1 (lt) |
| SI (1) | SI2635257T1 (lt) |
| SM (1) | SMT201700392T1 (lt) |
| WO (1) | WO2012061815A2 (lt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| PT2610345E (pt) | 2007-11-27 | 2016-01-11 | Medicago Inc | Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina |
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| JP5813513B2 (ja) | 2008-12-09 | 2015-11-17 | ノババックス，インコーポレイテッド | 修飾ｒｓｖｆタンパク質及びその使用方法 |
| HRP20220478T1 (hr) | 2009-09-22 | 2022-05-27 | Medicago Inc. | Način pripreme proteina od biljaka |
| EP3246019B1 (en) * | 2010-11-05 | 2021-03-03 | Novavax, Inc. | Rabies glycoprotein virus-like particles (vlps) |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| KR101963792B1 (ko) * | 2011-06-13 | 2019-07-31 | 메디카고 인코포레이티드 | 식물에서 광견병 바이러스 유사 입자 생성 |
| KR101479668B1 (ko) | 2012-07-31 | 2015-01-12 | 대한민국 | 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물 |
| CN103777021B (zh) * | 2012-10-18 | 2016-03-02 | 辽宁成大生物股份有限公司 | 狂犬疫苗糖蛋白含量的检测方法 |
| EP3344291B1 (en) | 2015-09-03 | 2024-11-27 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| CN106905434B (zh) * | 2017-02-28 | 2021-01-26 | 国药中生生物技术研究院有限公司 | 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 |
| EP3420076B1 (en) * | 2017-03-06 | 2024-02-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| EP4382183A3 (en) * | 2017-03-06 | 2024-08-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| EP3658118A4 (en) | 2017-07-24 | 2021-03-31 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE |
| US11992526B2 (en) * | 2017-11-06 | 2024-05-28 | Intervet Inc. | Rabies virus vaccine |
| MX2020009682A (es) | 2018-03-19 | 2020-10-12 | Novavax Inc | Vacunas de nanoparticulas multivalentes contra la influenza. |
| KR102077772B1 (ko) | 2018-11-29 | 2020-02-17 | 주식회사 바이오앱 | 광견병 예방용 백신 조성물 및 이의 제조 방법 |
| KR102211077B1 (ko) * | 2019-01-16 | 2021-02-02 | 충남대학교 산학협력단 | 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신 |
| CN109959789B (zh) * | 2019-04-12 | 2022-08-16 | 长春西诺生物科技有限公司 | 一种狂犬病毒抗体检测试纸及其制备方法与检测方法 |
| CN110007080B (zh) * | 2019-04-12 | 2022-09-23 | 长春西诺生物科技有限公司 | 一种狂犬病毒抗体定量检测试剂盒及其制备方法与检测方法 |
| WO2023064931A1 (en) * | 2021-10-15 | 2023-04-20 | La Jolla Institute For Immunology | Engineered rabies virus glycoprotein, compositions, and methods of use thereof |
| CN114272367B (zh) * | 2021-12-03 | 2023-07-07 | 华东理工大学 | 一种口服狂犬病病毒样颗粒疫苗及其制备方法 |
| KR102566969B1 (ko) | 2021-12-14 | 2023-08-16 | 안희철 | 근거리 통신 과정에서 충전 가능한 모바일 단말 |
| CN117867029B (zh) * | 2023-12-29 | 2024-12-20 | 复百澳(苏州)生物医药科技有限公司 | 一种狂犬亚型假病毒的制备方法及应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0237686A1 (en) * | 1986-03-18 | 1987-09-23 | Institut Pasteur | DNA sequences derived from the rabies virus genome |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5667782A (en) | 1992-07-16 | 1997-09-16 | Oxford University | Multiple particulate antigen delivery system |
| US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
| US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| US6589533B1 (en) * | 1997-09-18 | 2003-07-08 | Research Development Foundation | Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype |
| US6673601B1 (en) * | 1999-04-15 | 2004-01-06 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
| AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| US8535650B2 (en) * | 2001-12-03 | 2013-09-17 | Soligenix, Inc. | Stabilized reverse micelle compositions and uses thereof |
| US7211378B2 (en) * | 2002-01-31 | 2007-05-01 | Wisconsin Alumni Research Foundation | Filovirus vectors and noninfectious filovirus-based particles |
| AU2003213065A1 (en) | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Novel insect cell line |
| US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US9216212B2 (en) * | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| WO2007083644A1 (ja) * | 2006-01-17 | 2007-07-26 | Dnavec Corporation | 新規タンパク質発現系 |
| WO2007144886A2 (en) * | 2006-06-15 | 2007-12-21 | Ben-Gurion University Of The Negev Research And Development Authority | Virus-like particles for treatment of viral infections |
| US20100143406A1 (en) | 2006-06-30 | 2010-06-10 | Gale Smith | Methods of enhancing protein incorporation into virus like particles |
| US8980281B2 (en) | 2006-09-05 | 2015-03-17 | Academia Sinica | High-yield transgenic mammalian expression system for generating virus-like particles |
| TW200907058A (en) * | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| CN101801412A (zh) * | 2007-07-19 | 2010-08-11 | 诺瓦瓦克斯股份有限公司 | 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原 |
| KR100961280B1 (ko) * | 2008-05-21 | 2010-06-03 | 한국생명공학연구원 | 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도 |
| WO2009153801A1 (en) | 2008-06-17 | 2009-12-23 | Manpreet Kaur | Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof |
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| JP5813513B2 (ja) * | 2008-12-09 | 2015-11-17 | ノババックス，インコーポレイテッド | 修飾ｒｓｖｆタンパク質及びその使用方法 |
| EP3246019B1 (en) | 2010-11-05 | 2021-03-03 | Novavax, Inc. | Rabies glycoprotein virus-like particles (vlps) |
-
2011
- 2011-11-07 EP EP17179212.0A patent/EP3246019B1/en active Active
- 2011-11-07 HU HUE11838942A patent/HUE034247T2/en unknown
- 2011-11-07 US US13/883,745 patent/US9724405B2/en active Active
- 2011-11-07 LT LTEP11838942.8T patent/LT2635257T/lt unknown
- 2011-11-07 AU AU2011323090A patent/AU2011323090B2/en active Active
- 2011-11-07 JP JP2013537909A patent/JP6158088B2/ja active Active
- 2011-11-07 SM SM20170392T patent/SMT201700392T1/it unknown
- 2011-11-07 CN CN201810963479.7A patent/CN109157658A/zh active Pending
- 2011-11-07 KR KR1020137014262A patent/KR101847908B1/ko active IP Right Grant
- 2011-11-07 ES ES11838942.8T patent/ES2636965T3/es active Active
- 2011-11-07 SG SG2013034178A patent/SG190140A1/en unknown
- 2011-11-07 PL PL11838942T patent/PL2635257T3/pl unknown
- 2011-11-07 DK DK11838942.8T patent/DK2635257T3/en active
- 2011-11-07 RS RS20170786A patent/RS56157B1/sr unknown
- 2011-11-07 WO PCT/US2011/059602 patent/WO2012061815A2/en active Application Filing
- 2011-11-07 SI SI201131258T patent/SI2635257T1/en unknown
- 2011-11-07 CN CN201180064287.9A patent/CN103282023B/zh active Active
- 2011-11-07 CA CA2817005A patent/CA2817005C/en active Active
- 2011-11-07 BR BR112013011194-1A patent/BR112013011194B1/pt active IP Right Grant
- 2011-11-07 PT PT118389428T patent/PT2635257T/pt unknown
- 2011-11-07 EP EP11838942.8A patent/EP2635257B1/en active Active
- 2011-11-07 MX MX2013005090A patent/MX354750B/es active IP Right Grant
-
2016
- 2016-09-27 JP JP2016188777A patent/JP6195965B2/ja active Active
-
2017
- 2017-06-30 US US15/638,955 patent/US10086065B2/en active Active
- 2017-08-08 HR HRP20171213TT patent/HRP20171213T1/hr unknown
- 2017-08-11 CY CY20171100873T patent/CY1119284T1/el unknown
-
2018
- 2018-08-30 US US16/116,990 patent/US20190224307A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2635257T3 (pl) | Cząstki wirusopodobne (vlp) glikoproteiny wirusa wścieklizny | |
| HRP20180706T1 (hr) | Kimerna gripa nalik čestici koja sadrži hemaglutinin | |
| IL210215A0 (en) | Influenza virus-like particles (vlps) comprising hemagglutinin | |
| EP2536428A4 (en) | UNIVERSAL INFLUENZA VACCINES WITH VIRUSIC PARTICLES | |
| HK1202442A1 (en) | Vaccines against hpv hpv | |
| GB201005005D0 (en) | New vaccine | |
| HK1198703A1 (en) | Hpv chimaeric particle hpv | |
| EP2538969A4 (en) | VACCINES FROM POLYSACCHARIDE PARTICLES | |
| IL231132A0 (en) | Viral cleaning methods | |
| AU2012307348A8 (en) | Vaccine | |
| HK1203837A1 (en) | Immunogenic hpv l2-containing vlps and related compositions and methods hpv l2 vlp | |
| HK1200179A1 (en) | Increasing virus-like particle yield in plants | |
| EP2707480A4 (en) | PSEUDOVIRAL PARTICLES (VLPs) AND PREPARATION METHOD THEREOF | |
| GB201001726D0 (en) | Bunyavirus vaccine | |
| SI2739725T1 (sl) | Postopek za čiščenje od virusov-podobnih delcev | |
| EP2881401A4 (en) | EXTREMELY EFFICIENT METHOD OF PURIFYING VIRAL PSEUDO PARTICLES OF HUMAN PAPILLOMAVIRUS | |
| IL220941A0 (en) | Method for producing recombinant virus | |
| IL226187B (en) | Virus-like glycoprotein particles in rabies | |
| GB201013365D0 (en) | Hypertension vaccine | |
| AU2011900657A0 (en) | Vaccine | |
| GB0920319D0 (en) | HPV vaccine |